SEC Form NT 10-Q filed by Ra Medical Systems Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

 SEC FILE NUMBER

001-38677

 NOTIFICATION OF LATE FILING

 CUSIP NUMBER

74933X203

(Check one):

☐ Form 10-K

☐ Form 20-F

☐ Form 11-K

☒ Form 10-Q

☐ Form 10-D

☐ Form N-CEN

☐ Form N-CSR

For Period Ended: September 30, 2023

☐

 Transition Report on Form 10-K

☐

 Transition Report on Form 20-F

☐

 Transition Report on Form 11-K

☐

 Transition Report on Form 10-Q

☐

 Transition Report on Form N-SAR

For the Transition Period Ended: ___________________

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

Catheter Precision, Inc.

Full Name of Registrant

Ra Medical Systems, Inc.

Former Name if Applicable

1670 Highway 160 West, Suite 205

Address of Principal Executive Office (Street and Number)

Fort Mill, SC  29708

City, State and Zip Code

 (a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 ☐

 (b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 (c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

The registrant was unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 within the prescribed time period without unreasonable effort or expense because it required additional time to complete certain analyses related to the purchase price allocation of Catheter Precision, Inc. in order that it could file its Form 10-Q for the quarter ended June 30, 2023. The registrant now believes that those calculations are close to being finalized, and that all anticipated changes in estimates of purchase price and related estimated line items preliminarily reported in the registrant’s Form 10-Q for the quarter ended March 31, 2023 will be reflected as changes to estimates in the registrant’s Form 10-Q for the quarter ended June 30, 2023. 

The Registrant intends to file the Forms 10-Q for the quarters ended June 30, 2023 and September 30, 2023 as soon as it is able to obtain sign off from its independent auditors.

(1)

Name and telephone number of person to contact in regard to this notification

Steven Passey

801 

631-0747

(Name)

(Area Code)

(Telephone Number)

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes ☐     No ☒

The registrant has not filed its Form 10-Q for the quarter ended June 30, 2023.

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☒     No ☐

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Following the merger with Catheter Precision, Inc. on January 9, 2023, the registrant’s business focus has shifted to Catheter’s products.  As a result, the registrant’s revenues and results of operations for the quarter and nine months ended September 30, 2023 relate primarily to Catheter’s products, while revenues and results of operations for the quarter and nine months ended September 30, 2022 related to legacy Ra Medical products which are no longer being pursued by the registrant.  Accordingly, this means that the financial results for the respective quarterly and nine-month periods are not comparable.  The registrant is able to preliminarily estimate revenues of approximately $133,000 for the quarter ended September 30, 2023, and $314,000 for the nine months ended September 30, 2023, while revenues of $0 were reported for the quarter ended September 30, 2022, and revenues of $14,000 were reported for the nine months ended September 30, 2022. Complete, final results for the quarter and nine months ended September 30, 2023 are not available for the reasons stated above. The foregoing information is preliminary and is subject to adjustment when final numbers are reported. Adjustments could result from a number of factors including but not limited to the input of the Company's auditors as they complete the review process.

Date: November 15, 2023

By:

/s/ Steven Passey

Steven Passey

Chief Financial Officer and Secretary